ImmunityBio, Inc. (NASDAQ:IBRX)
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
Loses money on what it sells.
- Revenue
- $165.8M
- Net income
- -$992.4M
- Net margin
- -598.6%
Not enough balance-sheet detail to judge the debt load.
- Total debt
- $813.1M
- Cash
- $75.7M
Comfortably covers what is due within a year.
- Current assets
- $439.0M
- Current liabilities
- $76.7M
- Current ratio
- 5.72
Consumes cash and must keep raising it.
- Operating cash flow
- -$281.1M
- Free cash flow
- -$288.5M
- FCF margin
- -174.0%
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 1050.1M
- Share growth (1y)
- 18.2%
- Cash runway
- 3 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
IBRX Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 51.24 M | 44.21 M | 38.28 M | 32.06 M | 26.43 M | 16.52 M |
| Revenue Growth (YoY) | 93.91 % | 167.64 % | 406.95 % | 425.07 % | 2423.88 % | 41192.50 % |
| Cost of Revenue | 298.00 K | 238.00 K | 4.25 M | 4.13 M | 136.00 K | 58.00 K |
| Gross Profit | 50.94 M | 43.97 M | 34.04 M | 27.93 M | 26.29 M | 16.46 M |
| SG&A Expense | 50.63 M | 44.46 M | 37.83 M | 32.83 M | 42.34 M | 32.65 M |
| R&D Expense | 57.69 M | 64.77 M | 60.81 M | 50.73 M | 55.24 M | 48.23 M |
| Operating Expenses | 112.64 M | 113.76 M | 98.72 M | 83.56 M | 97.57 M | 80.89 M |
| Operating Income | -61.70 M | -69.79 M | -64.68 M | -55.63 M | -71.28 M | -64.43 M |
| Pretax Income | -230.39 M | -632.79 M | -62.09 M | -67.31 M | -92.31 M | -129.90 M |
| Tax Provision | 0.00 | -9.00 K | -135.00 K | -35.00 K | 269.00 K | -234.00 K |
| Net Income | -230.38 M | -632.78 M | -61.94 M | -67.25 M | -92.56 M | -129.65 M |
| EPS (Basic) | -0.22 | -0.62 | -0.06 | -0.07 | -0.10 | -0.15 |
| EPS (Diluted) | -0.22 | -0.62 | -0.06 | -0.07 | -0.10 | -0.15 |
| Shares Outstanding | 1.05 B | 1.03 B | 989.68 M | 946.60 M | 888.22 M | 853.16 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.